RBC reiterates Abbott at top pick

RBC Capital Markets analyst Phil Nalbone reiterated Abbott Laboratories at top pick, average risk, and a $55 price target. The Transcatheter Cardiovascular Therapeutics meeting could be a coming out party of sorts for Abbott Vascular, according to the analyst. The Abbott investor presentation provided a detailed look into the Vascular business, including two physician presentations on the Xience drug-eluting stent platform. Officials reiterated the company's goal of achieving $3 billion in sales and $0.15 in earnings per share from the Vascular division by 2009. Shares of the Abbott Park, Ill.-based biopharmaceutical company were down 71 cents, or 1.45%, at $48.12. (NYSE: ABT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.